The genetic removal of USP22 led to the suppression of liver cancer growth, boosted tumor immunogenicity and the presence of tumor-infiltrating lymphocytes, and heightened the effectiveness of therapies targeting PD-L1 and CDDP-based chemotherapy in mouse models (111). This evidence concerns the gene USP22 and neoplasm.